Mr. Michael Frank reports

REVIVE THERAPEUTICS TO EXPAND BUCILLAMINE IP AND ORPHAN DRUG PORTFOLIO ACROSS MEDICAL COUNTERMEASURES AND RARE DISEASES

Revive Therapeutics Ltd. has outlined its strategy to strengthen and expand the intellectual property and regulatory portfolio supporting bucillamine across medical countermeasures and rare diseases.

Revive's objective is to build bucillamine into a differentiated therapeutic franchise with multiple potential development and commercialization pathways. The strategy is centred on strengthening intellectual property protection, expanding into additional international markets, pursuing new orphan and rare disease opportunities, and engaging government and industry partners where bucillamine may address unmet preparedness or medical needs.

Building the bucillamine franchise:

• Expand and strengthen intellectual property: Revive intends to pursue additional patent protection and international opportunities covering potential uses of bucillamine in MCMs, biodefence, pandemic preparedness and selected rare diseases.
• Expand the orphan disease portfolio: Bucillamine currently has two U.S. Food and Drug Administration orphan drug designations for the treatment of cystinuria and the prevention of ischemia-reperfusion injury during liver transplantation. Revive intends to evaluate additional rare disease indications where bucillamine's anti-oxidant, anti-inflammatory and thiol-donating properties may provide a scientific and development rationale.
• Pursue government MCM opportunities.: Revive is investigating potential government programs in the United States, Canada and internationally that may support research, development, non-dilutive funding, procurement and potential stockpiling of bucillamine for medical countermeasure applications.
• Create partnering opportunities: By developing a broader intellectual property, regulatory and scientific foundation around bucillamine, Revive aims to create opportunities for partnerships with government agencies, defence organizations, pharmaceutical companies and other strategic parties.

Revive's existing intellectual property includes Canadian patent No. 3,172,170 covering the use of bucillamine in the treatment or prevention of infectious diseases, as well as pending U.S. and Canadian patent applications covering compositions, methods and uses of bucillamine in victims exposed to chemical warfare agents.

The company's MCM strategy is also supported by its continuing work with Defence Research and Development Canada -- Suffield Research Centre. In August, 2026, Revive reported positive findings from a DRDC research study evaluating bucillamine in an established model of nerve agent exposure. Additional confirmatory research is expected to further evaluate bucillamine's potential role in addressing the effects of nerve agent exposure.

"Our goal is to build bucillamine into a protected and partner-ready franchise rather than pursue individual indications in isolation," said Michael Frank, chief executive officer of Revive. "We already have an important foundation through our intellectual property, two FDA orphan drug designations and the research conducted with DRDC. Our next step is to strengthen that foundation internationally, identify additional rare disease opportunities, pursue government medical countermeasure programs, and create multiple pathways for partnering and commercialization."

Revive believes that a broader portfolio of patents, regulatory designations and government-supported development opportunities could increase the strategic value and partnerability of bucillamine while providing multiple potential pathways to commercialization.

The company intends to provide further updates as intellectual property initiatives, orphan disease evaluations, government opportunities and potential strategic partnerships advance.

About Revive Therapeutics Ltd.

Revive Therapeutics is a life science company focused on the research and development of therapeutics for biodefence and pandemic preparedness. The company is advancing bucillamine across potential medical countermeasure and rare disease applications, and is evaluating opportunities to strengthen its therapeutic portfolio.

We seek Safe Harbor.